| Similar Articles |
|---|
 |
The Motley Fool
June 2, 2009
Brian Orelli |
Pfizer: If You Can't Beat 'Em, Join 'Em Sutent fails. Again.   |
The Motley Fool
September 9, 2011
Frank Vinluan |
GSK Halts Part of Breast Cancer Trial; Drug Can't Top Herceptin GlaxoSmithKline has halted part of a phase 3 breast cancer clinical study after an independent committee concluded that the GSK drug administered alone is unlikely to work better than a rival cancer drug from Roche. |
The Motley Fool
June 29, 2007
Brian Orelli |
The Phase 2 Blues Drug developer Cytokinetics disappoints investors with failed clinical trials. |
The Motley Fool
January 8, 2010
Brian Orelli |
Pfizer's Having a Garage Sale Rather than sending its unwanted drugs to the trash bin, the giant drugmaker is striking deals with its comrades to take them off its hands. |
Chemistry World
September 2, 2014
Phillip Broadwith |
Exelexis slashes workforce by 70% The move follows poor results from a clinical trial of its cancer drug Cometriq (cabozantinib) in men with metastatic castration-resistant prostate cancer. |
The Motley Fool
May 9, 2007
Mike Havrilla |
Scintillating Synta Patient investors should peek at this pharma's promising pipeline. |
The Motley Fool
April 28, 2009
Brian Orelli |
Headline? Bad! Unexpected? No! For a company that only has one drug on the market, stopping a failing phase 3 clinical trial that's designed to expand the market of that drug is usually a major blow. But Onyx Pharmaceuticals was able to shrug it off. |
The Motley Fool
July 15, 2008
Brian Orelli |
Will a New Use Help Schering-Plough's Near-Blockbuster Drug? Delaying relapses probably won't be enough to get its Pegintron approved as a treatment for melanoma. |
The Motley Fool
November 22, 2010
Brian Orelli |
Pfizer's Mixed Bag Pfizer had a mixed bag of clinical trial results at the end of last week. And probably the company would have rather seen the results flip-flopped. |
The Motley Fool
December 5, 2006
Brian Lawler |
Slight Setback for Onyx Onyx shares fell on disappointing news, but there are other opportunities for the one-drug wonder. |
The Motley Fool
April 3, 2009
Brian Orelli |
Pfizer + Sutent = One Exciting Roller Coaster This time on the down slope, unfortunately. |
Pharmaceutical Executive
June 9, 2014 |
Immunotherapies: The New Hope for Cancer Treatment The Cancer Research Institute is clearing a path to the future of immunotherapeutics. Ben Comer speaks to its CEO and director of scientific affairs, Jill O'Donnell-Tormey |
The Motley Fool
May 4, 2009
Robert Steyer |
Beyond Provenge -- The Next Hot Cancer Drug? The search for prostate cancer treatments is filled with prospects and littered with failures. Which companies have the best chance of success? |
The Motley Fool
March 21, 2007
Brian Lawler |
New Indication for Pain Pain Therapeutics brings a new drug into the clinic. When drug companies attempt to bring new drugs that are outside of their core competencies to market, investors always need to be wary. |
The Motley Fool
June 14, 2007
Brian Lawler |
Dueling Fools: GlaxoSmithKline Bull Shares of the pharmaceutical may be temporarily down, but it's not out. |
The Motley Fool
September 28, 2010
Brian Orelli |
Pfizer's Sutent Fails. Again! No surprise here. |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
Chemistry World
August 27, 2014
Phillip Broadwith |
Clinical collaborations drive cancer immunotherapy A joint clinical trial agreement between Merck & Co and Pfizer is the latest in a rather tangled web of tie-ups between companies with cancer drugs that harness patients' immune systems. |
The Motley Fool
May 24, 2010
Brian Orelli |
ASCO Abstracts -- Pops and Drops! Ever since The American Society of Clinical Oncology began posting abstracts on-line -- and before that when they were sent to attendees -- investors have clamored to get a glimpse at the data. Here's your glimpse. |
The Motley Fool
January 22, 2010
Brian Orelli |
Pfizer's Great Data Won't Do Much The full data from a clinical trial testing Pfizer's Sutent in pancreatic cancer was truly amazing. Unfortunately, it's not going to do very much for the stock or Pfizer's bottom line. |
Chemistry World
October 17, 2012
Maria Burke |
GSK pledge on trials transparency GlaxoSmithKline has announced a series of initiatives to make clinical trial data publically available that could set a precedent in an industry not known for its transparency. |
BusinessWeek
June 16, 2011
Langreth & Cortez |
When Two Cancer Drugs Are Better Than One Drugmakers are collaborating to test combinations of genetically targeted cancer drugs in hopes of boosting survival rates. |
The Motley Fool
December 24, 2009
Brian Orelli |
Another Reason to Worry About Pfizer The FDA fails to approve Lyrica for treating anxiety. |
The Motley Fool
May 14, 2008
Brian Lawler |
Teaching Old Drugs New Tricks Pfizer's top drugs post mixed results in recent off-label studies. |
BusinessWeek
August 26, 2010
Tom Randall |
Cocktails Are Next For Cancer-Drug Makers Taking a cue from the cocktails of drugs that have made AIDS survivable, drugmakers are pursuing combination therapies against cancer. |
The Motley Fool
March 13, 2009
Brian Orelli |
Pfizer Finally Gets a Hit! Positive results on Pfizer's cancer drug Sutent come earlier than expected. |
The Motley Fool
November 27, 2006
Brian Lawler |
Teva and Pfizer Make Up The companies decide to play nice over generic versions of two of Pfizer's drugs. |
The Motley Fool
February 25, 2009
Brian Orelli |
Pfizer Doesn't Like Reruns The company drops two drugs that had made it as far as phase 3 trials. |
The Motley Fool
April 27, 2009
Jim Mueller |
Foolish Forecast: Pfizer's Out of the Starting Gate In advance of earnings, analyst's expect revenue down 6%, but none are saying to dump the stock. |
Chemistry World
February 7, 2013
Maria Burke |
GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public. |
The Motley Fool
June 9, 2010
Brian Orelli |
ASCO Pops and Drops Themes and company news from the annual meeting of the American Society of Clinical Oncology. |
The Motley Fool
August 28, 2009
Brian Orelli |
Abbott Signs Up Another One Abbott announces that it has set up a partnership with Pfizer to run tests on Pfizer's new drug. |
Chemistry World
May 31, 2013
Phillip Broadwith |
Two new 'personalized' cancer drugs approved Two new drugs for the most deadly kind of skin cancer have been approved by the US Food and Drug Administration. The drugs are only effective in patients whose tumors express specific genetic mutations, which can be identified using a device approved alongside the drugs. |
The Motley Fool
January 15, 2009
Robert Steyer |
For Pfizer, a Big Buy Could Be a Big Mistake Pfizer's CEO says the company must make a big, bold buy to reverse course on its skidding stock and to blast it out of its revenue doldrums. Is it the right move? |
Chemistry World
April 20, 2009
Phil Taylor |
GSK and Pfizer join forces in fight against HIV The world's two biggest pharmaceutical companies, GlaxoSmithKline (GSK) and Pfizer, are bundling their HIV activities into a joint venture company in a move they claim is both 'unique and innovative'. |
Chemistry World
June 12, 2014
Andy Extance |
Pharma vies to unleash immune system power on cancer Drug firms are investing heavily in clinical trials and collaborations as they seek to capitalize on the potential of cancer therapies that enlist or enhance our immune systems' ability to fight tumors. |
The Motley Fool
October 9, 2008
Brian Orelli |
When Science, Marketing, and Investing Collide How a pharmaceutical tries to sell more drugs can provide clues about its management. |
Chemistry World
December 21, 2015
Katrina Kramer |
BioAtla and Pfizer to collaborate on antibody research BioAtla and Pfizer will share expertise to develop tumor-targeting antibodies chemically bound to cytotoxic drugs. |
The Motley Fool
November 13, 2009
Brian Orelli |
Questioning Pfizer's Integrity Pfizer's epilepsy drug Neurontin has had generic competition for a few years, but it's still plaguing the pharmaceutical giant. |
Science News
May 13, 2000 |
Cancer Net CancerNet is a huge compendium of information on cancer assembled by the National Cancer Institute.... |
The Motley Fool
June 23, 2009
Brian Orelli |
Wonder Drug! Maybe? Get the facts before jumping on this one. |
Chemistry World
September 17, 2013
Phillip Broadwith |
GSK criticized for trial data secrecy An Italian research institute has withdrawn from a public -- private partnership after quarrelling with GlaxoSmithKline about access to data from an antibiotic clinical trial being run by the institute. |
The Motley Fool
April 16, 2009
Brian Orelli |
2 Virus Killers Are Better Than 1 Glaxo brings Pfizer under its HIV wing. |
The Motley Fool
March 25, 2011
Brian Orelli |
Pfile Pfizer Under "Potential" Researchers reported promising finding from a clinical trial of Pfizer's new drug, CP-870,893, in pancreatic cancer patients in the most recent issue of the journal Science. |
The Motley Fool
June 2, 2009
Brian Orelli |
ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies. |
The Motley Fool
May 21, 2010
Brian Orelli |
And You Thought Biotech Was High-Risk, High-Reward Large clinical trials make cardiovascular drugs risky, but the rewards are there, too. |
The Motley Fool
October 1, 2008
Brian Orelli |
Is Pfizer the Mystery Bidder? A few signals that Pfizer might be the one bidding on ImClone. |
The Motley Fool
June 24, 2011
Brian Orelli |
Come on, Pfizer, Not Even a Little Hint? Remoxy is rejected, but why? |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
